Exploratory analysis of epidemiological and clinicopathological characteristics of soft tissue sarcomas: a single institutional study in Chennai

Shaoni Parai; B. Ramkumar; G. Raja; Atul J. G.; Manish Kumar Sharma; Vasanth Rooban Narasimman

doi:10.18203/2320-6012.ijrms20243713

Authors

Shaoni Parai Department of Medical Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India
B. Ramkumar Department of Medical Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India
G. Raja Department of Medical Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India
Atul J. G. Department of Medical Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India
Manish Kumar Sharma Department of Medical Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India
Vasanth Rooban Narasimman Department of Medical Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20243713

Keywords:

GIST, Overall survival, Progression free survival, Prognostic factors, Soft tissue sarcoma, Treatment outcomes

Abstract

Background: Soft tissue sarcomas (STS) from mesenchymal origin form diverse and complex group. Gastrointestinal stromal tumors (GIST)s are most common mesenchymal neoplasm of gastrointestinal system. Better comprehension of clinicopathological profile needed to improve overall prognosis. The objective is to study the epidemiological, clinicopathological characteristics, treatment outcome and other prognostic factors predicting overall survival (OS) and progression free survival (PFS) in STS.

Methods: This study was conducted in Medical Oncology Department, Govt Royapettah Hospital, Chennai. It is a retrospective study, data retrieved from recorded files of patients with soft tissue sarcomas presented from Jan 2017-Dec 2021, and two years follow up data collected till Dec 2023.

Results: In this study 92 patients with soft tissue sarcoma were analysed. Most commonly found histological subtype was GIST (29.3 %). In our study OS rate at 2 years (years) was 0.80. PFS rate at 2 years was 0.70. Surgical status, staging showed correlation with PFS in GIST in cox regression analysis and both PFS, OS in non-GIST sarcomas. In non-GIST sarcomas grade had correlation with PFS and Staging found as an independent factor associated with PFS. Site of primary in GIST and histopathology in non-GIST STS also showed correlation.

Conclusions: In this study median OS and PFS not reached till the last date of follow up. Surgical status and staging found to be significant prognostic factors for both GIST and non-GIST sarcomas and grade in non-GIST sarcomas.

Metrics

Metrics Loading ...

References

Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922-30.

Mastrangelo G, Coindre JM, Ducimetière F, Dei Tos AP, Fadda E, Blay JY, et al. Incidence of soft tissue sarcoma and beyond: A population-based prospective study in 3 European regions. Cancer. 2012;118(21):5339-48.

ErikssonM. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21(Suppl 7):vii270-vii276.

Reichardt P. Soft tissue sarcomas, a look into the future: different treatments for different subtypes. Future Oncol. 2014;10(8Suppl):s19-27.

Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20.

Nilsson B, Bümming P, Meis‐Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the pre imatinib mesylate era-a population-based study in western Sweden. Cancer. 2005;103(4):821-9.

Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastro intestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39-46.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-80.

Lopez Gordo S, Bettonica C, Miró M, Estremiana F, Aranda H, Farran L. Gastric and small intestine GIST: results of 156 cases in 20 years. J Gastrointest Cancer. 2022;53(2):451-9.

Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2(1):14.

Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S, et al. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma. 2014;2014(1):145764.

Bajpai J, Khanna N, Vora T, Gulia A, Laskar S, Puri A, et al. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes. Ind J Cancer. 2018;55(1):37-44.

Rastogi S, Sharma A, Aggarwal A, Barwad A, Dhamija E, Panday R. Outcomes of advanced soft tissue sarcoma from dedicated medical oncology sarcoma clinic in North India and evaluation of the respective model. JCO. 2018;36(suppl_15):e23561.

Shukla NK, Deo SV. Soft tissue sarcoma-review of experience at a tertiary care cancer centre. Ind J Surg Oncol. 2011;2(4):309-12.

Saltus CW, Calingaert B, Candrilli S, Lorenzo M, D’yachkova Y, Otto T, et al. Epidemiology of adult soft-tissue sarcomas in Germany. Sarcoma. 2018;2018(1):5671926.

George A, Grimer R. Early symptoms of bone and soft tissue sarcomas: could they be diagnosed earlier.? Ann R Coll Surg Engl. 2012;94(4):261-6.

Díaz Casas SE, Villacrés JM, Lehmann Mosquera C, García Mora M, Mariño Lozano I, Ángel Aristizábal J, et al. Prognostic factors associated with tumor recurrence and overall survival in soft tissue sarcomas of the extremities in a Colombian Reference Cancer Center. Curr Oncol. 2024;31(4):1725-38.

ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102-12.

Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54.

Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15(11):1667-72.

Albertsmeier M, Rauch A, Roeder F, Hasenhütl S, Pratschke S, Kirschneck M, et al. External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25(3):754-67.

Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010;116(19):4613-21.

Rosenberg SA, Tepper JO, Glatstein EL, Costa JO, Baker AL, Brennam M, et al. The treatment of soft tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305-15.

Albertsmeier M, Rauch A, Roeder F, Hasenhütl S, Pratschke S, Kirschneck M, et al. External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25:754-67.

Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15(1):78.

Shivarudraiah SM, Viswanath S, Pandalanghat S, Soneji D, Kumar M, Patel A, et al. Adult soft tissue sarcoma: a prospective observational real-world data. Ind J Medi Paed Oncol. 2021;42(04):339-45.

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2017. Bethesda, MD: National Cancer Institute; 2020.

Colapkulu-Akgul N, Gunel H, Beyazadam D, Ozsoy MS, Alimoglu O. Gastrointestinal stromal tumors: recurrence and survival analysis of 49 patients. Middle East J Dig Dis. 2023;15(1):19.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.

Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265-74.

Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30(4):477-89.

Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33.

Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B, et al. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer. 2016;52:173-80.

Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99(1):42-7.

Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:465-75.

Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244(2):176-84.

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-8.

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34(3):244-250.

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014;120(15):2325-33.